Out of Sight - A Report Into Diabetic Eye Disease in Australia was produced by Baker IDI and the Centre for Eye Research Australia.
In 2015 Bayer commissioned Deloitte Access Economics to produce a report entitled The economic impact of diabetic macular oedema in Australia - A report on the epidemiology, treatment and economic impact of diabetic macular oedema in Australia.
Impact of diabetic retinopathy on vision-specific function.
36 month results of the pivotal phase 3 RISE and RIDE studies assessing Lucentis (ranibizumab) for diabetic macular edema.
24 month results of the pivotal phase 3 VIVID and VISTA studies assessing Eylea (aflibercept) for diabetic macular edema.
The Diabetic Retinopathy Clinical Research Network (DRCR.net) study compares aflibercept, bevacizumab and ranibizumab to treat diabetic macular edema.
The Bevordex study compared the use of Avastin (bevacizumab) with Ozurdex (dexamethasone implant) over 24 months for diabetic macular edema.